Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
Critical Reviews in Oncology/Hematology|August 12, 2018
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysisVincenzo Di Nunno, Emmanuele De Luca, Consuelo Buttigliero, et al.
Cancer Treatment Reviews|May 9, 2024
Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trialsMarcello Tucci, Marta Mandarà, Jacopo Giuliani, et al.
Cells|February 15, 2022
New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and BeyondAlessandro Audisio, Consuelo Buttigliero, Marco Donatello Delcuratolo, et al.
Cancer Treatment Reviews|August 20, 2018
De novo metastatic castration sensitive prostate cancer: State of art and future perspectivesClaudia Mosillo, Roberto Iacovelli, Chiara Ciccarese, et al.
Endocrine-Related Cancer|May 5, 2021
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCCFabio Turco, Marcello Tucci, Rosario Francesco Di Stefano, et al.
Critical Reviews in Oncology/Hematology|June 2, 2020
Bipolar androgen therapy in prostate cancer: Current evidences and future perspectivesGianmarco Leone, Consuelo Buttigliero, Chiara Pisano, et al.
Cells|March 10, 2022
Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to BedsideAntonio Ungaro, Marcello Tucci, Alessandro Audisio, et al.
Journal of Clinical Medicine|January 23, 2024
Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell CarcinomaAlessandro Samuelly, Rosario Francesco Di Stefano, Fabio Turco, et al.
Prostate Cancer and Prostatic Diseases|December 14, 2023
Safety profile of darolutamide versus placebo: a systematic review and meta-analysisFabio Turco, Silke Gillessen, Giorgio Treglia, et al.
Minerva Urology and Nephrology|March 30, 2021
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamideChiara Pisano, Marcello Tucci, Rosario F DI Stefano, et al.
Pageof 9